Gray Stacy W, O'Grady Cristin, Karp Lauren, Smith Daniel, Schwartz J Sanford, Hornik Robert C, Armstrong Katrina
Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1303-11. doi: 10.1158/1055-9965.EPI-08-0825. Epub 2009 Mar 24.
Direct-to-consumer (DTC) BRCA testing may expand access to genetic testing and enhance cancer prevention efforts. It is not known, however, if current DTC websites provide adequate risk information for informed medical decision making.
A total of 284 women with a personal or family history of breast/ovarian cancer were randomly assigned to view a "mock" DTC commercial website [control condition (CC); n = 93] or the same "mock" website that included information on the potential risks of obtaining genetic testing online. Risk information was framed two ways: risk information attributed to expert sources (ES; n = 98) and unattributed risk information (URI; n = 93). Participants completed an online survey. End points were intentions to get BRCA testing, testing site preference, and beliefs about DTC BRCA testing.
The sample was 82% white, had a mean age of 39 years (range, 18-70 years) and had a mean education of 3 years of college. Women exposed to risk information had lower intentions to get BRCA testing than women in the CC [adjusted odds ratio (OR), 0.48; 95% confidence interval (95% CI) 0.26-0.87; P = 0.016], and less positive beliefs about online BRCA testing (adjusted OR, 0.48; 95% CI, 0.27-0.86; P = 0.014). Women in the ES condition were more likely to prefer clinic-based testing than were women in the CC (adjusted OR, 2.05; 95% CI, 1.07-3.90; P = 0.030).
Exposing women to information on the potential risks of online BRCA testing altered their intentions, beliefs, and preferences for BRCA testing. Policy makers may want to consider the content and framing of risk information on DTC websites as they formulate regulation for this rapidly growing industry.
直接面向消费者(DTC)的BRCA检测可能会扩大基因检测的可及性,并加强癌症预防工作。然而,目前尚不清楚DTC网站是否能提供足够的风险信息以支持做出明智的医疗决策。
共有284名有个人或家族性乳腺癌/卵巢癌病史的女性被随机分配,分别浏览一个“模拟”DTC商业网站[对照条件组(CC);n = 93],或浏览同一个包含在线进行基因检测潜在风险信息的“模拟”网站。风险信息以两种方式呈现:归因于专家来源的风险信息(ES;n = 98)和无归因的风险信息(URI;n = 93)。参与者完成一项在线调查。终点指标为进行BRCA检测的意向、检测地点偏好以及对DTC BRCA检测的看法。
样本中82%为白人,平均年龄39岁(范围18 - 70岁),平均受教育年限为大学3年。接触风险信息的女性进行BRCA检测的意向低于CC组女性[调整后的优势比(OR)为0.48;95%置信区间(95%CI)为0.26 - 0.87;P = 0.016],且对在线BRCA检测的看法也不那么积极(调整后的OR为0.48;95%CI为0.27 - 0.86;P = 0.014)。ES组的女性比CC组的女性更倾向于选择基于诊所的检测(调整后的OR为2.05;95%CI为1.07 - 3.90;P = 0.030)。
让女性接触在线BRCA检测潜在风险的信息,改变了她们对BRCA检测的意向、看法和偏好。政策制定者在为这个快速发展的行业制定监管规定时,可能需要考虑DTC网站上风险信息的内容和呈现方式。